Trending News

San Diego
#AACR #Cancer research #Events #Oncology

News from AACR 2024: Tuesday’s highlights

Today, National Cancer Institute leaders discussed cancer breakthroughs and the importance of securing support from lawmakers for the NCI and National Institutes of Health in the session ‘The Cancer Moonshot: Opportunities to Fulfill the Vision of the National Cancer Plan – Dedicated to the Memory of Sen. Dianne… Read More

#Cancer Research #News #Trending News

San Diego
#AACR #Cancer research #Events #Oncology

News from AACR 2024: Monday’s highlights

A round-up of the latest news from the American Association of Cancer Research (AACR) Annual Meeting. Symposiums UCLA: Dr Zev Wainberg, Co-Director of the UCLA Health GI Oncology Program, presented results from pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators, which suggests that for… Read More

#Cancer Research #News #Trending News

San Diego
#AACR #Cancer research #Events #Oncology

News from AACR 2024: Sunday’s highlights

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science. The session ‘Inspiring Science, Fueling Progress, Revolutionizing Care’ featured a distinguished panel of cancer… Read More

#Cancer Research #News #Trending News

#Cardiovascular disease #FDA #Hypertension #Idorsia #Phase II trial

FDA approval represents ‘transformational progress’ in hypertension

The US Food and Drug Administration (FDA) has approved Tryvio (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Tryvio (aprocitentan) is an endothelin receptor antagonist that inhibits the binding of endothelin… Read More

#News #Regulatory #Trending News

Gene therapy
#Cell and gene therapy #FDA #Gene therapy #Orchard Therapeutics #Paediatrics #Rare disease

First gene therapy for children with rare disease gets US sign-off

Lenmeldy (atidarsagene autotemcel) has become the first Food and Drug Administration (FDA)-approved gene therapy for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD). Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system. It is… Read More

#News #Regulatory #Trending News

CAR-T therapy
#Blood cancer #Bristol Myers Squibb #CAR-T #Cell therapy #FDA #Leukaemia #Oncology

FDA approves first CAR-T cell therapy for relapsed CLL or SLL

The US Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It is approved in adult patients who have received at least two… Read More

#News #Regulatory #Trending News

Vaccine vial and syringe
#Covid variants #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Omicron

Vaccine monitoring crucial as SARS-CoV-2 evolves

UK researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to evolve. The Francis Crick Institute and the National Institute for Health and Care Research Biomedical Research Centre at University College Hospitals London (UCLH) published their… Read More

#News #Trending News

CT scans of the brain
#Alzheimer's #Galimedix Therapeutics #Neurodegenerative disorders #Neuroscience #Preclinical investigations

New drug shows promising neuroprotective effects

Galimedix Therapeutics has announced data showing small molecule GAL-201 has neuroprotective and symptomatic alleviation potential in models of Alzheimer’s disease (AD). These new findings support previous studies where GAL-201 was characterised as a promising development candidate for the treatment of AD (Russ et. al. 2022). Read More

#News #Trending News

#Artificial intelligence (AI) #Cancer Research UK #Oncology #Prostate cancer #University of East Anglia #University of Oxford

AI reveals prostate cancer is not just one disease

Research published in Cell Genomics has shown that prostate cancer includes two different subtypes of the disease, also known as evotypes. This discovery was made by using artificial intelligence (AI) to help unlock new discoveries about the evolution of prostate cancer and could lead to the… Read More

#Cancer Research #News #Trending News

FDA
#Adverse event #FDA #Myeloma #Oncology #Oncopeptides

FDA withdraws approval of Oncopeptides’ Pepaxto

The US Food and Drug Administration (FDA) has announced its final decision to withdraw approval of Pepaxto (melphalan flufenamide), despite an appeal by manufacturer Oncopeptides. The drug was originally approved for use in combination with dexamethasone to treat some patients with multiple myeloma. Approval was withdrawn as the confirmatory study… Read More

#News #Regulatory #Trending News

#FDA #Finance #GlobalData #Minerva Biosciences #Neuroscience #Schizophrenia

Minerva value plummets following FDA rejection of roluperidone

The stock market value of Minerva Biosciences has dropped nearly 60%, following the US Food and Drug administration (FDA) decision not to approve roluperidone for symptoms of schizophrenia. The company received a ‘Complete Response Letter’ from the FDA highlighting the clinical deficiencies in its new drug… Read More

#News #Trending News

#Astellas Pharma #CAR-T #Cell therapy #Collaboration #Immuno-oncology #In vivo #Kelonia Therapeutics #Xyphos Biosciences

Companies agree $800m deal for in vivo CAR-T cell therapy

Astellas-owned Xyphos Biosciences and Kelonia Therapeutics have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics. Under the terms of the agreement, the companies plan to combine Kelonia’s iGPS with Xyphos’ ACCEL technology to develop in vivo CAR-T cell therapies targeting up to two programmes. Kevin… Read More

#Business & Investment #News #Trending News

T cells attacking cancer
#Cell and gene therapy #Cell therapy #FDA #Iovance #Melanoma #Oncology #Solid tumours

FDA approves first T cell therapy in solid tumours

The US Food and Drug Administration has approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of metastatic, unresectable melanoma. It is approved for use in adults that have previously been treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or… Read More

#News #Regulatory #Trending News

Boston waterfront
#AI / data analytics / healthtech / informatics #Lab automation #Lab technology #SLAS2024

SLAS2024: Day Two Highlights

Scientific sessions Tuesday’s presentations spanned a range of topics, including functional genomics for target identification, next-generation proteomics, self-driving laboratories, the future of cell culture, and ‘lab on a particle’ technology. There were some great talks on the DDW-hosted Ignite Theater track, co-sponsored by Hamamatsu Corporation and… Read More

#News #Trending News

Vaccine vial and syringe
#Cancer vaccine #Imperial College London #Moderna #mRNA-based vaccines #Oncology #Phase I trial

First UK patients receive experimental mRNA therapy for cancer

The first UK patients have received an mRNA cancer therapy – mRNA-4359 – as part of a Phase I/II clinical trial investigating its potential for treating melanoma, lung cancer and other solid tumour cancers. The Mobilize trial is run in partnership between Imperial College London and… Read More

#Cancer Research #News #Trending News